Literature DB >> 17325217

Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm.

Yseult F Brun1, Carly G Dennis, William R Greco, Ralph J Bernacki, Paula J Pera, Jennifer J Bushey, Richard C Youn, Donald B White, Brahm H Segal.   

Abstract

Response surface methods for the study of multiple-agent interaction allow one to model all of the information present in full concentration-effect data sets and to visualize and quantify local regions of synergy, additivity, and antagonism. In randomized wells of 96-well plates, Aspergillus fumigatus was exposed to various combinations of amphotericin B, micafungin, and nikkomycin Z. The experimental design was comprised of 91 different fixed-ratio mixtures, all performed in quintuplicate. After 24 h of drug exposure, drug effect on fungal viability was assessed using the tetrazolium salt 2,3-bis {2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide} (XTT) assay. First, we modeled each fixed-ratio combination alone using the four-parameter Hill concentration-effect model. Then, we modeled each parameter, including the 50% inhibitory concentration (IC(50)) effect, versus the proportion of each agent using constrained polynomials. Finally, we modeled the three-agent response surface overall. The overall four-dimensional response surface was complex, but it can be explained in detail both analytically and graphically. The grand model that fit the best included complex polynomial equations for the slope parameter m and the combination index (equivalent to the IC(50) for a fixed-ratio concentration, but with concentrations normalized by the respective IC(50)s of the drugs alone). There was a large region of synergy, mostly at the nikkomycin Z/micafungin edge of the ternary plots for equal normalized proportions of each drug and extending into the center of the plots. Applying this response surface method to a huge data set for a three-antifungal-agent combination is novel. This new paradigm has the potential to significantly advance the field of combination antifungal pharmacology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17325217      PMCID: PMC1855564          DOI: 10.1128/AAC.01007-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

Review 1.  In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors:  William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

2.  Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Guillermo Garcia-Effron; Laura Alcazar-Fuoli; Emilia Mellado; Maria J Buitrago; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens.

Authors:  D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 4.  Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

Authors:  M M McNeil; S L Nash; R A Hajjeh; M A Phelan; L A Conn; B D Plikaytis; D W Warnock
Journal:  Clin Infect Dis       Date:  2001-07-30       Impact factor: 9.079

5.  Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm.

Authors:  Yseult F Brun; Carly G Dennis; William R Greco; Ralph J Bernacki; Paula J Pera; Jennifer J Bushey; Richard C Youn; Donald B White; Brahm H Segal
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

Review 6.  Current approaches to diagnosis and treatment of invasive aspergillosis.

Authors:  Brahm H Segal; Thomas J Walsh
Journal:  Am J Respir Crit Care Med       Date:  2005-12-30       Impact factor: 21.405

7.  Combination antifungal therapy for invasive aspergillosis.

Authors:  Kieren A Marr; Michael Boeckh; Rachel A Carter; Hyung Woo Kim; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2004-08-27       Impact factor: 9.079

8.  Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients.

Authors:  O Ringdén; F Meunier; J Tollemar; P Ricci; S Tura; E Kuse; M A Viviani; N C Gorin; J Klastersky; P Fenaux
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

Review 9.  Toward more effective antifungal therapy: the prospects of combination therapy.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Br J Haematol       Date:  2004-07       Impact factor: 6.998

10.  Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus.

Authors:  William C Nierman; Arnab Pain; Michael J Anderson; Jennifer R Wortman; H Stanley Kim; Javier Arroyo; Matthew Berriman; Keietsu Abe; David B Archer; Clara Bermejo; Joan Bennett; Paul Bowyer; Dan Chen; Matthew Collins; Richard Coulsen; Robert Davies; Paul S Dyer; Mark Farman; Nadia Fedorova; Natalie Fedorova; Tamara V Feldblyum; Reinhard Fischer; Nigel Fosker; Audrey Fraser; Jose L García; Maria J García; Arlette Goble; Gustavo H Goldman; Katsuya Gomi; Sam Griffith-Jones; Ryan Gwilliam; Brian Haas; Hubertus Haas; David Harris; H Horiuchi; Jiaqi Huang; Sean Humphray; Javier Jiménez; Nancy Keller; Hoda Khouri; Katsuhiko Kitamoto; Tetsuo Kobayashi; Sven Konzack; Resham Kulkarni; Toshitaka Kumagai; Anne Lafon; Anne Lafton; Jean-Paul Latgé; Weixi Li; Angela Lord; Charles Lu; William H Majoros; Gregory S May; Bruce L Miller; Yasmin Mohamoud; Maria Molina; Michel Monod; Isabelle Mouyna; Stephanie Mulligan; Lee Murphy; Susan O'Neil; Ian Paulsen; Miguel A Peñalva; Mihaela Pertea; Claire Price; Bethan L Pritchard; Michael A Quail; Ester Rabbinowitsch; Neil Rawlins; Marie-Adele Rajandream; Utz Reichard; Hubert Renauld; Geoffrey D Robson; Santiago Rodriguez de Córdoba; Jose M Rodríguez-Peña; Catherine M Ronning; Simon Rutter; Steven L Salzberg; Miguel Sanchez; Juan C Sánchez-Ferrero; David Saunders; Kathy Seeger; Rob Squares; Steven Squares; Michio Takeuchi; Fredj Tekaia; Geoffrey Turner; Carlos R Vazquez de Aldana; Janice Weidman; Owen White; John Woodward; Jae-Hyuk Yu; Claire Fraser; James E Galagan; Kiyoshi Asai; Masayuki Machida; Neil Hall; Bart Barrell; David W Denning
Journal:  Nature       Date:  2005-12-22       Impact factor: 49.962

View more
  4 in total

1.  Trehalose 6-phosphate phosphatase is required for cell wall integrity and fungal virulence but not trehalose biosynthesis in the human fungal pathogen Aspergillus fumigatus.

Authors:  Srisombat Puttikamonkul; Sven D Willger; Nora Grahl; John R Perfect; Navid Movahed; Brian Bothner; Steven Park; Padmaja Paderu; David S Perlin; Robert A Cramer
Journal:  Mol Microbiol       Date:  2010-06-09       Impact factor: 3.501

2.  Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm.

Authors:  Yseult F Brun; Carly G Dennis; William R Greco; Ralph J Bernacki; Paula J Pera; Jennifer J Bushey; Richard C Youn; Donald B White; Brahm H Segal
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

3.  An application of a Hill-based response surface model for a drug combination experiment on lung cancer.

Authors:  Shaoyang Ning; Hongquan Xu; Ibrahim Al-Shyoukh; Jiaying Feng; Ren Sun
Journal:  Stat Med       Date:  2014-06-18       Impact factor: 2.373

4.  Kinetic interpretation of log-logistic dose-time response curves.

Authors:  Walter W Focke; Isbe van der Westhuizen; Ndeke Musee; Mattheüs Theodor Loots
Journal:  Sci Rep       Date:  2017-05-22       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.